ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891)
Sahebjam S, Forsyth P, Tran N, Mokhtari S, Arrington J, Jaglal M, Etame A, Liu J, Wicklund M, Gatewood T, Macaulay R, Robinson T, Yu M. ATIM-08. A PHASE I TRIAL OF PEMBROLIZUMAB AND VORINOSTAT COMBINED WITH TEMOZOLOMIDE AND RADIATION THERAPY FOR NEWLY DIAGNOSED GLIOBLASTOMA (NCT03426891). Neuro-Oncology 2018, 20: vi2-vi2. PMCID: PMC6216125, DOI: 10.1093/neuonc/noy148.005.Peer-Reviewed Original ResearchAdverse eventsPD-1/PD-L1 antibodiesDay 1Sequential dose-escalation cohortsOngoing phase I trialDose level 2Dose-escalation cohortsCommon adverse eventsDose level 1Phase II doseMonth survival ratePD-L1 antibodiesPhase I trialDose-escalation designPrimary study objectiveTumor immune recognitionPre-clinical experimentsEligible ptsMaintenance temozolomideSafety cohortConcurrent radiotherapySecondary endpointsEscalation cohortsI trialEscalation design